Compare MAGN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | MYGN |
|---|---|---|
| Founded | 1864 | 1991 |
| Country | United States | United States |
| Employees | 8500 | N/A |
| Industry | Paper | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 444.2M |
| IPO Year | N/A | 1996 |
| Metric | MAGN | MYGN |
|---|---|---|
| Price | $13.52 | $5.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $12.00 | $7.64 |
| AVG Volume (30 Days) | 314.5K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $5.37 | $6.86 |
| Revenue Next Year | $3.47 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $7.82 | $3.53 |
| 52 Week High | $15.52 | $8.59 |
| Indicator | MAGN | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 59.09 |
| Support Level | $13.15 | $5.57 |
| Resistance Level | $15.24 | $6.26 |
| Average True Range (ATR) | 0.63 | 0.32 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 64.44 | 42.61 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.